Literature DB >> 22368694

The importance of screening and prenatal diagnosis in the identification of the numerical chromosomal abnormalities.

Daniela Neagos1, Ruxandra Cretu, Roxana Corina Sfetea, Laurentiu Camil Bohiltea.   

Abstract

BACKGROUND AND AIMS: The obstetric care of a pregnancy, as it is practiced today, includes non-invasive screening approaches as well as invasive procedures for the definitive prenatal diagnosis of fetal disorders correlations between indications for prenatal cytogenetic diagnosis and results of the chromosomal analysis made upon fetal cells. The aim of our study was to evaluate the correlations between the screening test results and results of chromosomal analysis on fetal cells.
METHODS: Amniotic fluid samples from 1159 pregnant women were studied with the rapid FISH method and the cytogenetic analysis (karyotype). The results from both methods were compared.
RESULTS: The indications to perform prenatal cytogenetic diagnosis for numerical chromosomal abnormalities were: abnormal results of double or triple test, advanced maternal age, fetal abnormality detected through ultrasound examination, and positive family history for chromosomal anomalies. In our study we identified 30 cases with abnormal numeric chromosomes (18 cases of trisomy 21, 4 cases of trisomy 18, 3 cases of trisomy X, 1 case of monosomy, 2 cases of trisomy XYY, 1 case of trisomy XXY and 1 case of triploidy).
CONCLUSIONS: This report confirms the importance of screening and the cytogenetic diagnosis in the identification of the numerical chromosomal abnormalities.

Entities:  

Keywords:  amniotic fluid; aneuploidy; prenatal diagnosis; prenatal screening

Year:  2011        PMID: 22368694      PMCID: PMC3282538     

Source DB:  PubMed          Journal:  Maedica (Bucur)        ISSN: 1841-9038


  23 in total

1.  Influence of cigarette-smoking on the result of the triple test.

Authors:  E Hafner; G Stangl; A Rosen; K Schuchter; M Plattner; K Philipp
Journal:  Gynecol Obstet Invest       Date:  1999       Impact factor: 2.031

2.  Second-trimester dimeric inhibin-A in Down's syndrome screening.

Authors:  K Spencer; E M Wallace; S Ritoe
Journal:  Prenat Diagn       Date:  1996-12       Impact factor: 3.050

3.  Accuracy of cytogenetic findings on chorionic villus sampling (CVS)--diagnostic consequences of CVS mosaicism and non-mosaic discrepancy in centres contributing to EUCROMIC 1986-1992.

Authors:  J M Hahnemann; L O Vejerslev
Journal:  Prenat Diagn       Date:  1997-09       Impact factor: 3.050

4.  Rapid prenatal diagnosis of chromosomal aneuploidies by fluorescence in situ hybridization: clinical experience with 4,500 specimens.

Authors:  B E Ward; S L Gersen; M P Carelli; N M McGuire; W R Dackowski; M Weinstein; C Sandlin; R Warren; K W Klinger
Journal:  Am J Hum Genet       Date:  1993-05       Impact factor: 11.025

5.  Rapid molecular method for prenatal detection of Down's syndrome.

Authors:  B Pertl; S C Yau; J Sherlock; A F Davies; C G Mathew; M Adinolfi
Journal:  Lancet       Date:  1994-05-14       Impact factor: 79.321

6.  The Korean collaborative study on 11,000 prenatal genetic amniocentesis.

Authors:  Y H Yang; K S Ju; S B Kim; Y H Cho; J H Lee; S H Lee; O H Choi; J H Chun; J I Kim; H J Kim; Y S Sohn
Journal:  Yonsei Med J       Date:  1999-10       Impact factor: 2.759

7.  Quad screen as a predictor of adverse pregnancy outcome.

Authors:  Lorraine Dugoff; John C Hobbins; Fergal D Malone; John Vidaver; Lisa Sullivan; Jacob A Canick; Geralyn M Lambert-Messerlian; T Flint Porter; David A Luthy; Christine H Comstock; George Saade; Keith Eddleman; Irwin R Merkatz; Sabrina D Craigo; Ilan E Timor-Tritsch; Stephen R Carr; Honor M Wolfe; Mary E D'Alton
Journal:  Obstet Gynecol       Date:  2005-08       Impact factor: 7.661

8.  The clinical application of interphase FISH in prenatal diagnosis.

Authors:  E Pergament; P X Chen; M Thangavelu; M Fiddler
Journal:  Prenat Diagn       Date:  2000-03       Impact factor: 3.050

9.  Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination.

Authors:  P T Dick
Journal:  CMAJ       Date:  1996-02-15       Impact factor: 8.262

10.  Meta-analysis of first trimester Down syndrome screening studies: free beta-human chorionic gonadotropin significantly outperforms intact human chorionic gonadotropin in a multimarker protocol.

Authors:  Mark I Evans; David A Krantz; Terrence W Hallahan; Robert S Galen
Journal:  Am J Obstet Gynecol       Date:  2007-03       Impact factor: 8.661

View more
  5 in total

1.  Clinical application of chromosomal microarray analysis for fetuses with craniofacial malformations.

Authors:  Chenyang Xu; Yanbao Xiang; Xueqin Xu; Lili Zhou; Huanzheng Li; Xueqin Dong; Shaohua Tang
Journal:  Mol Cytogenet       Date:  2020-08-25       Impact factor: 2.009

2.  The importance of rapid aneuploidy screening and prenatal diagnosis in the detection of numerical chromosomal abnormalities.

Authors:  Ghada M Elsayed; Lobna El Assiouty; Ezzat S El Sobky
Journal:  Springerplus       Date:  2013-09-29

3.  BACs-on-Beads technology: a reliable test for rapid detection of aneuploidies and microdeletions in prenatal diagnosis.

Authors:  Sandra García-Herrero; Inmaculada Campos-Galindo; José Antonio Martínez-Conejero; Vicente Serra; Inés Olmo; Coral Lara; Carlos Simón; Carmen Rubio
Journal:  Biomed Res Int       Date:  2014-03-27       Impact factor: 3.411

4.  Chromosomal abnormalities: subgroup analysis by maternal age and perinatal features in zhejiang province of China, 2011-2015.

Authors:  Xiao-Hui Zhang; Li-Qian Qiu; Ying-Hui Ye; Jian Xu
Journal:  Ital J Pediatr       Date:  2017-05-12       Impact factor: 2.638

Review 5.  Genetic counseling in the context of Bangladesh: current scenario, challenges, and a framework for genetic service implementation.

Authors:  Mohammad Jakir Hosen; Saeed Anwar; Jarin Taslem Mourosi; Sourav Chakraborty; Md Faruque Miah; Olivier M Vanakker
Journal:  Orphanet J Rare Dis       Date:  2021-04-09       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.